Drug Trial Radar · NCT05850520
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
892
Actual
Start
May 15, 2023
Primary completion
Nov 7, 2024
Study completion May 27, 2025
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- May 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO). In people with RVO, a blood vessel that carries blood away from the retina (vein) becomes blocked. The retina is the very back part of the eye. The blocked vein causes fluid and blood to leak into the retina and thereby causes a swelling of the macula (the center of the retina responsible for fine vision). This swelling is called macular edema. When a vein in the retina is blocked, the levels of a protein called vascular endothelial growth factor (VEGF) rises. VEGF helps the growth of new blood vessels. This can lead to macular edema and may cause the vision to become blurry. The study treatment intravitreal (IVT) aflibercept is given as an injection into the eye. It works by blocking VEGF and this can help repair vision problems related to RVO. IVT aflibercept is already available and is prescribed by doctors as the standard of care treatment for macula edema secondary to RVO. Standard of care is a treatment that medical experts consider most appropriate for a disease. Standard of care is given every 4 weeks in people with macula edema secondary to RVO. While repeated injections of aflibercept may prevent worsening of vision, it may place a burden on the patient. However, a higher amount (8 mg) compared to the standard of care (2 mg) of IVT aflibercept is being tested in studies. This higher amount could be given less often. The amount of IVT aflibercept given is measured in milligrams, also known as mg. The main purpose of this study is to learn how well a higher amount of the study treatment aflibercept works in people with macular edema secondary to RVO. To answer this, researchers will measure changes in vision called best corrected visual acuity (BCVA) in the study participants between study start and after 36 weeks of treatment. Changes will then be compared between those participants who received the higher amount of IVT aflibercept and those that received standard of care. To learn how safe the study treatment is in the participants, the researchers will count the number of participants from study start and up to 64 weeks later that have: * adverse events * serious adverse events "Adverse events" are any medical problems that the participants have during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think they might be related to the study treatments. An adverse event is considered "serious" when it leads to death, puts the participants' lives at risk, requires hospitalization, causes disability, causes a baby being born with medical problems or is otherwise medically important. Dependent on the treatment group, the participants will either receive the higher amount of aflibercept or standard of care as an intravitreal injection for up to 60 weeks. The study will consist of a test (screening) phase, a treatment phase and an end of study phase. Each participant will be in the study for up to 64 weeks. One visit to the study site is planned during the screening phase, followed by visits approximately every 4 weeks (16 in total) during treatment and one visit at the end of the study. During the study, the study doctors and their team will: * check patients' eye health using various eye examination techniques * measure patients' eye vision (BCVA) * take blood and urine samples * do physical examinations * check vital signs * examine heart health using electrocardiogram (ECG) * do pregnancy tests in women of childbearing age In addition, participants will be asked to fill a questionnaire on vision-related quality of life.
Conditions
- Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher doseDrug
Intravitreally (IVT) injection.
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mgDrug
Intravitreally (IVT) injection.
ShamDrug
Sham procedure will be given on visits when an active injection is not planned.
FluoresceinDiagnostic test
Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36Time frame: At Week 36
Locations
273 sites in 27 countries. Site status is shown where the registry gives one.
Retina Consultants of Orange County - Fullerton
Fullerton, California
South Coast Retina - Long Beach
Long Beach, California
Northern California Retina Vitreous Associates - Mountain View Office
Mountain View, California
Desert Retina Consultants - Palm Springs Office
Palm Springs, California
Azul Vision Pasadena
Pasadena, California
Retina Consultants of Southern California
Redlands, California
Retina Consultants of Southern Colorado, PC
Colorado Springs, Colorado
New England Retina Associates
New London, Connecticut
Rand Eye Institute
Deerfield Beach, Florida
National Ophthalmic Research Institute - Fort Myers
Fort Myers, Florida
The Eye Institute of West Florida - Largo
Largo, Florida
Florida Eye Associates - Melbourne Main Office
Melbourne, Florida
Florida Retina Institute - Orlando
Orlando, Florida
Retina Specialty Institute - Pensacola
Pensacola, Florida
Fort Lauderdale Eye Institute
Plantation, Florida
Retina Vitreous Associates of Florida - Saint Petersburg
St. Petersburg, Florida
East Florida Eye Institute
Stuart, Florida
Center for Retina and Macular Disease - Winter Haven
Winter Haven, Florida
Marietta Eye Clinic
Marietta, Georgia
Retina Associates - Elmhurst
Elmhurst, Illinois
University Retina and Macula Associates - Oak Forest
Oak Forest, Illinois
Retina Associates - Lenexa
Lenexa, Kansas
The Retina Care Center - Baltimore
Baltimore, Maryland
Cumberland Valley Retina Consultants | Hagerstown, MD
Hagerstown, Maryland
Mid Atlantic Retina Specialists - Hagerstown
Hagerstown, Maryland
Vitreo-Retinal Associates - Worcester
Grand Rapids, Michigan
RCM - St. Louis Park Retina Clinic
Saint Louis Park, Minnesota
Retina Consultants of Nevada - Summerlin
Las Vegas, Nevada
Retina Center of New Jersey
Bloomfield, New Jersey
NJ Retina - New Brunswick
New Brunswick, New Jersey
NJ Retina | Teaneck
Teaneck, New Jersey
Vision Research Center
Albuquerque, New Mexico
Vitreoretinal Consultants of NY - Great Neck
Great Neck, New York
Vitreoretinal Consultants of NY - Hauppauge
Hauppauge, New York
Ophthalmic Consultants of Long Island
Lynbrook, New York
Retina Associates of Western New York
Rochester, New York
Cincinnati Eye Institute - Blue Ash
Blue Ash, Ohio
Midwest Retina - Main Office
Dublin, Ohio
Retina Consultants, LLC
Salem, Oregon
Mid Atlantic Retina - Bethlehem
Bethlehem, Pennsylvania
Showing 40 of 273 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.